Abstract
Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.
Keywords: Deubiquitinating enzymes, drug discovery, ubiquitin, infectious diseases, post-translational modifications.
Current Pharmaceutical Design
Title:Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Volume: 19 Issue: 18
Author(s): Bindu Nanduri, Akamol E. Suvarnapunya, Malabi Venkatesan and Mariola J. Edelmann
Affiliation:
Keywords: Deubiquitinating enzymes, drug discovery, ubiquitin, infectious diseases, post-translational modifications.
Abstract: Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.
Export Options
About this article
Cite this article as:
Nanduri Bindu, Suvarnapunya Akamol E., Venkatesan Malabi and Edelmann Mariola J., Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180008
DOI https://dx.doi.org/10.2174/1381612811319180008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation On Molecular Graph Comparison
Current Computer-Aided Drug Design Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Lymphangiogenesis and Anti-Tumor Immune Responses
Current Molecular Medicine CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry A Novel Spider Peptide Toxin Suppresses Tumor Growth Through Dual Signaling Pathways
Current Molecular Medicine Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Disordered Interactome of Human Papillomavirus
Current Pharmaceutical Design